迈瑞医疗：研发投入比例和规模均在医疗器械企业中处于领先地位

Core Viewpoint - Company maintains a strong commitment to R&D investment, allocating approximately 10% of annual revenue to R&D, which is among the highest in the medical device industry [1][2] Group 1: R&D Investment - Cumulative R&D investment reached 21.556 billion yuan since the company went public in 2018, reinforcing its core R&D capabilities for future growth [1] - The company emphasizes the importance of R&D innovation as a driving force, continuously increasing investment to develop market-relevant products [1] Group 2: Industry Challenges - The development of medical devices, such as defibrillators, involves a lengthy process, taking up to ten years from R&D to market launch, with five years dedicated to establishing certification standards [2] - The company acknowledges that technological breakthroughs in medical devices require a gradual accumulation of knowledge and cannot be achieved through shortcuts [2] Group 3: Future Directions - The company plans to enhance R&D innovation by developing higher-performance reagents and clearer imaging devices for early disease detection, as well as more precise and user-friendly minimally invasive instruments [2] - The goal is to improve healthcare quality and efficiency while reducing costs, ultimately extending quality healthcare to a broader population [2]